• LEARN MORE ABOUT KEYNOTE 695
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact
OncoSec Medical Incorporated
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact

Press Releases

Investors

Investors

  • Overview
    • Profile
    • Contacts
  • Events & Presentations
  • Analysts
  • Press Releases
    • Email Alerts
  • Financial Info
  • Stock Info
    • Quote
    • Charts
    • Historical Data
  • Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • FAQ
  • Press Releases

  • Email Alerts

Clinical Cancer Research highlights OncoSec's Merkel Cell Carcinoma Clinical Study on the Cover of its February Issue

Feb 04, 2020 8:30am EST

OncoSec's Visceral Lesion Applicator (VLA) Electroporation Device Demonstrates Targeted Entry and Deployment in Both Lung and Liver in Data Presented at the Society of Interventional Oncology Annual Meeting

Feb 03, 2020 8:46am EST

OncoSec Urges Shareholders to Focus on the Critical Benefits of CGP/Sirtex Transaction

Jan 31, 2020 8:30am EST

OncoSec Urges Shareholders Not to Fall for Alpha’s Disingenuous “Proposal” and Scheme to Prevent Fair Vote at Special Meeting

Jan 28, 2020 8:30am EST

Data from OncoSec's Visceral Lesion Applicator (VLA) to be Presented at the Society of Interventional Oncology Annual Meeting

Jan 27, 2020 8:30am EST

OncoSec Announces the Appointment of Robert J. DelAversano, C.P.A, as Principal Accounting Officer and Controller

Jan 21, 2020 4:30pm EST

OncoSec Board Rejects Alpha Holdings “Proposal” and Announces New Special Meeting Date

Jan 16, 2020 8:30am EST

OncoSec Sends Letter to Shareholders Highlighting that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Have Recommended That OncoSec Shareholders Vote “FOR” the CGP/Sirtex Transaction on the WHITE Proxy Card

Jan 06, 2020 8:30am EST

Institutional Shareholder Services Inc. ("ISS") Recommends OncoSec Shareholders Vote “FOR” the CGP/Sirtex Transaction

Dec 26, 2019 8:30am EST

OncoSec Responds to Alpha’s “Proposal”

Dec 20, 2019 3:16pm EST
RSS
  • Prev
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • ...46
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    logo

    Sign Up for our mailing list to stay current on all of our exciting new research and developments.

    Get Email Alerts
    OncoSec’s investigational products have not been approved or cleared by the FDA.

    Links

    • About
    • Pipeline
    • Technology
    • Partnering
    • Patients
    • Media
    • Investors
    • Contact
    • KEYNOTE 695 CLINICAL TRIAL

    Contact

    New Jersey Headquarters
    820 Bear Tavern Road
    Suite 200
    Ewing, NJ 08628

    R&D Laboratories
    3565 General Atomics Court #100
    San Diego, CA 92121

    p | 855.662.6732
    f | 858.430.3832

    Investors@OncoSec.com


    © 2023 OncoSec Medical Incorporated. All Rights Reserved. Q12-003052-01 REV E.